Voting FOR the share increase allows Leo flexibility, with shares available for a wide range of uses. Leo has never diluted wildly, like some start-ups, so we know he'll put the new shares to good use.
A major pharma stakeholder might well want a seat on the BOD as well as ability to buy shares in the open market, after news is announced.
I believe there is one vacant seat, as well as the subsidiary to fill.
just sniffing at possible ongoing negotiations
News 
Market Data 
Discover 
AI
